Good news! In July 20th, 2017, Olymvax was notified of having passed the inspection of Good Manufacturing Practice and finally received the Certificate for its Haemophilus influenzae type b Conjugate Vaccine, issued by Sichuan Provincial Food and Drug Administration.
Step by step, Olymvax has achieved the Drug Registration License and GMP certificate for Hib conjugate vaccine, which means Olymvax’s Hib conjugate vaccine is officially approved for production and marketing. Hib conjugate vaccine batch production is soon coming. Under the strict supervision of CFDA, once each batch of the product get the “certificate for the release of biological products”the batch of vaccine is available on the market.